Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ani Pharmaceuticals (ANIP) EBITDA Margin: 2010-2024

Historic EBITDA Margin for Ani Pharmaceuticals (ANIP) over the last 15 years, with Dec 2024 value amounting to 1.30%.

  • Ani Pharmaceuticals' EBITDA Margin rose 2974.00% to 15.91% in Q3 2025 from the same period last year, while for Sep 2025 it was 8.70%, marking a year-over-year increase of 660.00%. This contributed to the annual value of 1.30% for FY2024, which is 989.00% down from last year.
  • Per Ani Pharmaceuticals' latest filing, its EBITDA Margin stood at 1.30% for FY2024, which was down 88.39% from 11.19% recorded in FY2023.
  • In the past 5 years, Ani Pharmaceuticals' EBITDA Margin registered a high of 11.19% during FY2023, and its lowest value of -15.87% during FY2021.
  • Over the past 3 years, Ani Pharmaceuticals' median EBITDA Margin value was 1.30% (recorded in 2024), while the average stood at 1.23%.
  • Its EBITDA Margin has fluctuated over the past 5 years, first plummeted by 1,543bps in 2020, then surged by 2,000bps in 2023.
  • Yearly analysis of 5 years shows Ani Pharmaceuticals' EBITDA Margin stood at -5.38% in 2020, then tumbled by 1,049bps to -15.87% in 2021, then surged by 705bps to -8.81% in 2022, then skyrocketed by 2,000bps to 11.19% in 2023, then tumbled by 989bps to 1.30% in 2024.